Trials / Active Not Recruiting
Active Not RecruitingNCT06253845
Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
A Phase 1b, Single Arm Study of CG0070 After Transurethral Resection in Patients With Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Investigators will evaluate the safety of CG0070 for the treatment of patients with Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CG0070 | CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with DDM and normal saline. |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2027-09-01
- Completion
- 2027-09-01
- First posted
- 2024-02-12
- Last updated
- 2026-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06253845. Inclusion in this directory is not an endorsement.